|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokineticsand pharmacodynamics of intravenous PEGylated recombinantmammalian urate oxidase in patients with refractory gout显示文摘 | SUNDY JS GANSON NJ KELLY SJ | 2007 | Ar-thritis Rheum2007，56，3： | 1 |
| 2 | Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout显示文摘 | Sundy JS Ganson NJ Kelly SJ | 2007 | Arthritis Rheum2007，56，： | 1 |
| 3 | Control of hyperuricemia in subjects with refractory gout,and induction of antibody against poly (ethylene glycol) (PEG) , in a phase I trial of subcutaneous PEGylated urate oxidase显示文摘 | Ganson NJ Kelly S J Scarlett E | 2006 | Arthritis Res Ther2006，8，1： | 1 |
| 4 | Control of hyperuricemia in subjects with refractory gout,and induction of antibody against poly (ethylene glycol) (PEG),in a phase Ⅰ trial of subcutaneous PEGylated urateoxidase显示文摘 | Ganson NJ Kelly SJ Scarlett E | 2006 | Arthritis Res Ther2006，8，1： | 1 |
| 5 | Control of hyperuricemia in subjects with refractory gout and induction of antibody against poly (ethylene glycol) (PEG) ,in a phase I trial of subcutaneous PEG y lated urate oxidase 显示文摘 | Ganson NJ Kelly SJ Searlett E | 2008 | Arthritis Res Ther2008，8，1： | 1 |
| 6 | Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout,including in organ transplant recipients显示文摘 | Hershfield MS Ganson NJ Kelly SJ | 2014 | Arthritis Res Ther2014，16，2： | 1 |
| 7 | Control of hyper- uricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol) (PEG) , in a phase I trial of subcutaneous PEGylated urate oxidase显示文摘 | Ganson NJ Kelly S J Scarlett E | 2006 | Arthritis Res Ther2006，8，1： | 1 |
| 8 | Control of hyperuricemia in subjects with refractory gout,and induction of antibody against poly(ethylene glycol)(PEG),in a phase I trial of subcutaneous PEGylated urate oxidase显示文摘 | Ganson NJ Kelly SJ Scarlett E | 2006 | Arthritis Res Ther2006，8，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员